The Lilly Foundation commits $1 million to support AMPATH Oncology Institute in Kenya
5 February 2015 | By Eli Lilly and Company
New funding builds on a longstanding partnership to help Kenyans receive quality care...
List view / Grid view
News
BIOTRONIK announces completion of patient enrollment in BIOFLOW-IV study evaluating safety and efficacy of Orsiro
5 February 2015 | By BIOTRONIK
BIOTRONIK, a leading manufacturer of cardio- and endovascular medical technology, announced that patient enrollment for the BIOFLOW-IV study has been completed...
Roche’s Phase III study of Gazyva/Gazyvaro showed significant benefit in refractory indolent non-Hodgkin’s lymphoma
4 February 2015 | By Roche
Roche announced positive results from the Phase III GADOLIN study, which evaluated treatment options for people with indolent non-Hodgkin’s lymphoma (iNHL) who are refractory to MabThera®/Rituxan® (rituximab) treatment...
AstraZeneca receives planning consent for new global R&D centre and corporate headquarters in Cambridge, UK
4 February 2015 | By AstraZeneca
AstraZeneca announced that Cambridge City Council has granted planning permission for the Company’s new global R&D centre and corporate headquarters in the City...
Genmab announces preliminary results in Phase II study of Daratumumab in double refractory multiple myeloma
4 February 2015 | By Genmab
Genmab A/S today announced preliminary results from the Phase II study of daratumumab in double refractory multiple myeloma conducted by its collaboration partner Janssen Biotech...
France’s pharmaceutical market value will crawl to $48.2 billion by 2020 as generics limit growth
4 February 2015 | By GlobalData
The French pharmaceutical market is forecast to grow at a tepid Compound Annual Growth Rate (CAGR) of 0.7% from $46.2 billion in 2014 to $48.2 billion by 2020, restricted by an increasing focus on generic drugs, according to research and consulting firm GlobalData...
Lilly Diabetes donates $92,000 in camp scholarships to the American Diabetes Association
3 February 2015 | By Lilly Diabetes
Today Lilly Diabetes announced its support of the American Diabetes Association (Association) summer camp program by donating $92,000 for camp scholarships...
AYOXXA and SERI to collaborate on protein biomarker detection
3 February 2015 | By AYOXXA Biosystems / SERI
AYOXXA and SERI will work together on validating the company’s multiplexing technology platform for protein biomarker detection, as part of an expanded collaboration for developing ophthalmic diagnostic tools...
Pierre Fabre Pharmaceuticals announce initiation of Phase IIa clinical trial program for F17464 in schizophrenia
3 February 2015 | By Pierre Fabre Pharmaceuticals
Pierre Fabre Pharmaceuticals has announced the initiation of a Phase IIa clinical trial program for F17464, a new selective dopamine D3 receptor antagonist, in schizophrenia. The trial is designed to assess the efficacy and safety of F17464 compared to placebo in patients with acute schizophrenia. The six-week multinational European trial…
Coulter Partners appoints Eskil Westh as Executive Vice President
3 February 2015 | By Coulter Partners
Coulter Partners, the Global Life Sciences search specialist, is pleased to announce the appointment of Eskil Westh as Executive Vice President...
Roche spends $1.03 billion for majority stake in Foundation Medicine
3 February 2015 | By Roche
Roche today announced that it has commenced a cash tender offer for up to 15,604,288 outstanding shares of common stock of Foundation Medicine, Inc. at a price of $50.00 per share...
Sanofi and MannKind announce Afrezza®, the only inhaled insulin, now available in the U.S.
3 February 2015 | By Sanofi / MannKind Corporation
Sanofi and MannKind Corporation announced today that Afrezza® (insulin human) Inhalation Powder, the only inhaled insulin, is now available by prescription in U.S. retail pharmacies nationwide. Afrezza is approved by the U.S. Food and Drug Administration to control high blood sugar in adults with type 1 and type 2 diabetes...
FDA approves first-in-class Glyxambi(R) (empagliflozin/linagliptin) tablets for adults with type 2 diabetes
3 February 2015 | By Eli Lilly
The U.S. FDA has approved Glyxambi® (empagliflozin/linagliptin) tablets, from Boehringer Ingelheim Pharmaceuticals and Eli Lilly and Company, as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes (T2D) when both empagliflozin and linagliptin are appropriate treatments...
Experts make pharma predictions for 2015: The good, the bad and the ugly
2 February 2015 | By CPhI Worldwide
Experts from CPhI Worldwide have shared their pharma predictions for 2015, suggesting that Continuous Manufacturing and QbD will expand, with FDA becoming ‘industry tutor’. However, pharma concerns about supply chain persist...
FDA grants Breakthrough Therapy Designation for Roche’s investigational cancer immunotherapy MPDL3280A
2 February 2015 | By Roche
US FDA has granted Breakthrough Therapy Designation for Roche’s investigational cancer immunotherapy MPDL3280A (anti-PDL1) in non-small cell lung cancer...
